Our writer reveals a very silly mistake he made earlier this year that has reduced the returns for his Stocks and Shares ISA.

Endpoints Weekly covers ASH conference highlights, FDA discussions on Moderna's RSV vaccine safety, Biosecure Act exclusion, and industry updates from biotech leaders.

After several severe RSV cases were reported in a pediatric trial of Moderna's vaccine, the FDA has partially paused testing ...

FDA advisors said that more data are needed to fully understand if there are broader safety concerns related to use of ...

The FDA has since put a hold on enrolling children under 2 years old and those ages 2 through 5 who have never been exposed ...

Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...

The FDA has placed a hold on all clinical studies of vaccines for respiratory syncytial virus in infants due to safety concerns following a trial involving two mRNA-based vaccine candidates from ...

Not providing some services in languages other than English is a violation of civil rights. It can also create public health ...

Along with holiday arrangements, changing seasons signal the need for another type of preparation: vaccination.

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...